AMGN

Amgen Inc.
CAPPED RATING

Amgen Inc is a U.S. based biotechnology company, with historical expertise in renal disease and cancer supportive care products. The firm discovers, develops, manufactures and delivers human therapeutics.

Amgen Inc. (AMGN) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B+); its weakest is Revisions (D-). The rating has held at C+ for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.7 / 5.0
C+
Value
B-
Factor Score 2.9 / 5.0
Growth
C-
Factor Score 2.1 / 5.0
Profitability
B+
Factor Score 3.8 / 5.0
Momentum
B+
Factor Score 3.8 / 5.0
Revisions
D-
Factor Score 0.9 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 27.0
EV / EBITDA 16.6
Rev Growth YoY 8.5%
Gross Margin 72.5%
Price Return 3M 11.7%
Price Return 12M 42.3%
Catalyst Signal +0.13
Market Cap $251.9B
TTM Revenue $38.9B
Price / Sales 6.5
ROE 78.4%

Historical Factor Score Progression

Held C+ for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-16 B- (2.9) C- (2.1) B+ (3.8) B+ (3.8) D- (0.9) C+ (2.7)
2026-11-09 B- (2.9) C (2.2) B+ (3.8) B+ (3.6) D- (0.9) C+ (2.7)
2026-11-06 C+ (2.8) C (2.3) B+ (3.8) B+ (3.8) D- (0.9) C+ (2.7)
2026-11-05 B- (2.9) C (2.3) B+ (3.8) B+ (3.7) D- (0.9) C+ (2.7)
2026-11-04 B- (2.9) C (2.3) B+ (3.8) B+ (3.7) D- (1.0) C+ (2.7)
Page 1 of 11
…